Remibrutinib is a selective Bruton's tyrosine kinase inhibitor used as an active pharmaceutical ingredient. It is an oral, targeted compound approved for chronic spontaneous urticaria and has been investigated in other inflammatory conditions.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 1787294-07-8
Ticagrelor sulphone
pharmaceutical raw material
(RS)-tegafur
pharmaceutical raw material
(1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-7H-purin-7-yl)acetic acid--4-(((2-amino-3,5-dibromophenyl)methyl)amino)cyclohexan-1-ol (1/1)
pharmaceutical raw material
Oxytocein (A)
pharmaceutical raw material
N-[3-[6-amino-5-[2-[methyl(prop-2-enoyl)amino]ethoxy]pyrimidin-4-yl]-5-fluoro-2-methylphenyl]-4-cyclopropyl-2-fluorobenzamide
CUABMPOJOBCXJI-UHFFFAOYSA-N
CC1=C(C=C(C=C1NC(=O)C2=C(C=C(C=C2)C3CC3)F)F)C4=C(C(=NC=N4)N)OCCN(C)C(=O)C=C